Lipase Elevation in Patients With COVID-19.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32496339.
- Also identified by DOI 10.14309/ajg.0000000000000732 and PMC identifier 7288768.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although coronavirus disease (COVID-19) has been associated with gastrointestinal manifestations, its effect on the pancreas remains unclear. We aimed to assess the frequency and characteristics of hyperlipasemia in patients with COVID-19. A retrospective cohort study of hospitalized patients across 6 US centers with COVID-19. Of 71 patients, 9 (12.1%) developed hyperlipasemia, with 2 (2.8%) greater than 3 times upper limit of normal. No patient developed acute pancreatitis. Hyperlipasemia was not associated with poor outcomes or symptoms. Although a mild elevation in serum lipase was observed in some patients with COVID-19, clinical acute pancreatitis was not seen.
Medical subject headings
- Coronavirus Infections
- Lipase
- Pancreatitis
- Pneumonia, Viral